Clinical trials: Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
This phase I trial studies the side effects and best dose of radiosurgery boost following chemoradiation in treating patients with locally advanced pancreatic cancer that may or may not be removed by surgery.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT01739439
- Testing
- gemcitabine hydrochloride, hyperfractionated radiation therapy, intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Fox Chase Cancer Center
Pancreatic Carcinoma
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
This is a prospective, randomized phase II trial. The aim of this study is to assess the efficacy of two therapeutics strategies.
- Trial name
- NCT02676349
- Testing
- mFolfirinox, Chemoradiotherapy, surgery
- Where
- 26 sites in France
- Volunteers
- 130 people
- Sponsor
- Institut de Cancérologie de Lorraine
Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy, Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy
A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
The investigators hypothesize that intensification of local therapy will lead to improvements in local control and survival in patients with unresectable and borderline resectable pancreatic cancer.
- Trial name
- NCT02207465
- Testing
- Radiotherapy, Abraxane
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
This phase II trial studies how well nab-paclitaxel and gemcitabine hydrochloride followed by radiation therapy before surgery work in treating patients with pancreatic cancer that can be removed by surgery.
- Trial name
- NCT02427841
- Testing
- Fluorouracil, Gemcitabine, Image Guided Radiation Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- OHSU Knight Cancer Institute
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer
This pilot clinical trial studies combination chemotherapy and radiation therapy before surgery followed by gemcitabine hydrochloride in treating patients with pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer
- Trial name
- NCT01821612
- Testing
- oxaliplatin, irinotecan, leucovorin
- Where
- 14 sites in United States
- Volunteers
- 23 people
- Sponsor
- Alliance for Clinical Trials in Oncology